Fragile X Syndrome: Supportive Treatment, Unmet Needs, and Paths to Novel Interventions and Disease-Targeted Therapies
Affiliation:
1. Elizabeth Berry-Kravis, Rush University Medical Center
Abstract
Abstract
Fragile X syndrome (FXS), as a monogenic cause of intellectual disability and autism spectrum disorder, has been one of the first neurodevelopmental disorders in which molecular and neuronal mechanisms of disease have been identified, leading to the concept of targeting the underlying disease to reverse symptoms. Translating findings in basic science and animal models to humans with FXS has proven difficult. These challenges have prompted the FXS field to organize to build interlocking projects to support initiatives to improve supportive care, make clinical research accessible to families, generate collaborative research on natural history and outcome measures, and create clinical trial consortia and novel trial designs.
Publisher
American Association on Intellectual and Developmental Disabilities (AAIDD)
Subject
Psychiatry and Mental health,Neurology (clinical),Arts and Humanities (miscellaneous),Developmental and Educational Psychology,Neuropsychology and Physiological Psychology,General Medicine,Pediatrics, Perinatology and Child Health
Reference22 articles.
1. Abbeduto,
L.,
Berry-Kravis,
E.,
Sterling,
A.,
Sherman,
S.,
Edgin,
J. O.,
McDuffie,
A.,
Hoffmann,
A.,
Hamilton,
D.,
Aschkenasy,
J.,
&
Thurman,A. J.
(2020).
Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: Feasibility, practice effects, test-retest reliability, and construct validity.
Journal of Neurodevelopmental Disorders,
12(1),
1–
23.
http://dx.doi.org/10.1186/s11689-020-09313-6 2. Berry-Kravis,
E.,
Des Portes,
V.,
Hagerman,
R.,
Jacquemont,
S.,
Charles,
P.,
Visootsak,
J.,
Brinkman,
M.,
Rerat,
K.,
Koumaras,
B.,
Zhu,
L.,
Barth,
G. M.,
Jaecklin,
T.,
Apostol,
G.,
&
Von Raison,F.
(2016).
Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Science Translational Medicine,
8(321),
321ra5–
321ra5.
http://dx.doi.org/10.1126/scitranslmed.aab4109 3. Berry-Kravis,
E.,
Erickson,
C. A.,
Hagerman,
R.,
Tartaglia,
N.,
Cohen,
J.,
Sebree,
T.,
Gutterman,
D.,
Tich,
N.,
Dobbins,
T.,
&
Palumbo,J. M.,
(2020,
October).
Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and Prognostic Biomarker.
Journal of the American Academy of Child & Adolescent Psychiatry, 59(10),
S265.
http://dx.doi.org/10.1016/j.jaac.2020.08.464 4. Berry-Kravis,
E.,
Hagerman,
R.,
Visootsak,
J.,
Budimirovic,
D.,
Kaufmann,
W. E.,
Cherubini,
M.,
Zarevics,
P.,
Walton-Bowen,
K.,
Wang,
P.,
Bear,
M. F.,
&
Carpenter,R. L.
(2017).
Arbaclofen in fragile X syndrome: Results of phase 3 trials.
Journal of Neurodevelopmental Disorders,
9(1),
1–
18.
http://dx.doi.org/10.1186/s11689-016-9181-6 5. Berry-Kravis,
E.,
Horrigan,
J. P.,
Tartaglia,
N.,
Hagerman,
R.,
Kolevzon,
A.,
Erickson,
C. A.,
Hatti,
S.,
Snape,
M.,
Yaroshinsky,
A.,
Stoms,
G.,
FXS-001 Investigators,
Glass,
L.,
&
Jones,N. E.
(2020).
A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome.
Pediatric Neurology,
110,
30–
41.
http://dx.doi.org/10.1016/j.pediatrneurol.2020.04.019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|